What is TAE Life Sciences?
TAE Life Sciences operates at the intersection of advanced physics and oncology, pioneering the development of Boron Neutron Capture Therapy (BNCT). The company's core innovation, the Alphabeam Neutron System, represents a paradigm shift in radiotherapy by enabling a biologically targeted approach that selectively destroys cancer cells while sparing surrounding healthy tissue. This precision-focused methodology is designed to address the limitations of conventional radiation treatments, offering a more efficient therapeutic window for patients with complex, treatment-resistant tumors. By streamlining the treatment process into a minimal number of sessions, TAE Life Sciences is effectively addressing the dual challenges of clinical efficacy and patient quality of life, positioning itself as a disruptive force in the global cancer care market.
How much funding has TAE Life Sciences raised?
TAE Life Sciences has raised a total of $70M across 2 funding rounds:
Series A
$40M
Series B
$30M
Series A (2018): $40M with participation from Artis Ventures Management Iii
Series B (2020): $30M led by Artis Ventures Management Iii
Key Investors in TAE Life Sciences
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness. The firm utilizes an engineering-first approach to back scalable medical technologies that leverage AI and advanced data analytics to develop personalized therapeutics.
What's next for TAE Life Sciences?
With the successful closure of its latest funding cycle, TAE Life Sciences is poised to accelerate its clinical development roadmap and infrastructure expansion. The strategic focus will likely shift toward the commercialization of the Alphabeam Neutron System, requiring significant investment in regulatory compliance, hospital partnerships, and the scaling of manufacturing capabilities. As the company navigates the complexities of the global healthcare landscape, the emphasis will remain on demonstrating long-term clinical outcomes that justify the adoption of BNCT as a primary treatment modality. Future growth will be defined by the firm's ability to integrate its technology into existing oncology centers, thereby establishing a new standard for precision radiotherapy that is both accessible and highly effective for diverse patient populations.
See full TAE Life Sciences company page
